title: Prognostic utility of gene therapy with herpes simplex virus thymidine kinase for patients with high-grade malignant gliomas: a systematic review and meta analysis.
abstract: The aim of this study was to assess the effectiveness of adding viral vector-mediated gene therapy with herpes simplex virus thymidine kinase (HSV-tk) to standard treatment, in comparison with standard treatment alone to treat patients with high-grade gliomas (HGGs). A literature search of the databases PubMed, Embase, the Cochrane Library, Web of Science, and Chinese biomedicine was performed to identify eligible studies. Three randomized controlled trials (involving a total of 532 patients) were included in this systematic review. A meta-analysis of included studies demonstrated a significant increase in median survival time (MST) in patients who were treated with HSV-tk gene therapy (mean deviation 0.59, 95% CI: 0.41-0.76, p < 0.0001). The results of pooled analysis for different patient groups show that overall survival (OS) for all HGG patients was improved by adding gene therapy [hazard ratio (HR) = 0.91, 95% CI: 0.74-1.13, p = 0.42], while a different result was seen for glioblastoma multiforme (GBM) patients (HR = 1.06, 95% CI: 0.80-1.41, p = 0.70). Furthermore, the combined results for tumor progression implied that standard therapy was superior to gene therapy [odds ratio (OR) = 1.31, p = 0.09]; yet differences in HR and OR between experimental groups and control groups had no statistical significance (p > 0.05). Based on the best available evidence, it appears that adding gene therapy with HSV-tk has some effect in treating HGG patients, especially with respect to MST. However, neither the pooled analysis of OS, nor the combined analysis of tumor progress indicates any significant advantage to adding gene therapy compared with standard treatment alone. More prospective studies are needed to draw solid conclusions about whether gene therapy has significant prognostic advantage.
authors.affiliation: Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.|Institution of Integrated Traditional Chinese with Western Medicine, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.|Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China.|School of Medicine, Northwest University of Nationality, Lanzhou, China.
authors.forename: Fei
authors.initials: F
authors.lastname: Zhao
authors.affiliation: Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.|Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China.
authors.forename: Jinhui
authors.initials: J
authors.lastname: Tian
authors.affiliation: School of Medicine, Northwest University of Nationality, Lanzhou, China.
authors.forename: Lifeng
authors.initials: L
authors.lastname: An
authors.affiliation: Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China. yangkehuebm2006@163.com.|Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China. yangkehuebm2006@163.com.
authors.forename: Kehu
authors.initials: K
authors.lastname: Yang
mesh_terms: D001932:Brain Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D018450:Disease Progression; D015316:Genetic Therapy; D005822:Genetic Vectors; D005910:Glioma / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D006801:Humans; D009367:Neoplasm Staging; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018139:Simplexvirus / Q000235:genetics*; D016019:Survival Analysis; D013937:Thymidine Kinase / Q000235:genetics*
chemical_list: D013937:Thymidine Kinase
references.citation: Nat Med. 1997 Dec;3(12):1354-61
references.pmid: 9396605
references.citation: J Neurooncol. 2003 Dec;65(3):269-78
references.pmid: 14682377
references.citation: J Clin Oncol. 2011 Sep 20;29(27):3611-9
references.pmid: 21844505
references.citation: Gene Ther. 1996 Jun;3(6):491-5
references.pmid: 8789798
references.citation: Future Oncol. 2010 Nov;6(11):1691-710
references.pmid: 21142657
references.citation: Gene Ther. 1999 Mar;6(3):330-7
references.pmid: 10435083
references.citation: Cancer Control. 2013 Jan;20(1):43-8
references.pmid: 23302906
references.citation: Lancet Oncol. 2013 Aug;14(9):823-33
references.pmid: 23850491
references.citation: Trials. 2007 Jun 07;8:16
references.pmid: 17555582
references.citation: Acta Neuropathol. 2007 Aug;114(2):97-109
references.pmid: 17618441
references.citation: Anticancer Agents Med Chem. 2011 Oct;11(8):739-47
references.pmid: 21707496
references.citation: J Neurooncol. 2004 Mar-Apr;67(1-2):177-88
references.pmid: 15072465
references.citation: Hum Gene Ther. 2000 Nov 20;11(17):2389-401
references.pmid: 11096443
references.citation: Mol Ther. 2000 Feb;1(2):195-203
references.pmid: 10933931
references.citation: J Neurooncol. 2003 Dec;65(3):279-89
references.pmid: 14682378
references.citation: Hum Gene Ther. 1995 Nov;6(11):1467-76
references.pmid: 8573619
references.citation: Gene Ther. 2000 Nov;7(21):1853-8
references.pmid: 11110418
references.citation: Hum Gene Ther. 2000 Nov 1;11(16):2197-205
references.pmid: 11084677
references.citation: J Craniomaxillofac Surg. 2011 Mar;39(2):91-2
references.pmid: 21145753
references.citation: Stat Med. 2002 Jun 15;21(11):1539-58
references.pmid: 12111919
references.citation: PLoS One. 2013 Aug 02;8(8):e71930
references.pmid: 23936532
references.citation: Cancer Lett. 2010 Apr 1;290(1):58-67
references.pmid: 19765892
references.citation: Science. 1992 Jun 12;256(5063):1550-2
references.pmid: 1317968
references.citation: Lancet Oncol. 2009 May;10(5):459-66
references.pmid: 19269895
references.citation: Hum Gene Ther. 1998 Nov 20;9(17):2595-604
references.pmid: 9853526
references.citation: Mol Ther. 2004 Nov;10(5):967-72
references.pmid: 15509514
references.citation: J Clin Neurosci. 2009 Dec;16(12):1595-8
references.pmid: 19793663
references.citation: Hum Gene Ther. 1999 Sep 20;10(14):2325-35
references.pmid: 10515452
references.citation: Mol Ther. 2003 Jun;7(6):851-8
references.pmid: 12788659
references.citation: Neuro Oncol. 1999 Jul;1(3):205-11
references.pmid: 11554389